general and administrative expenses of $71,000, primarily attributable to a decrease in travel expense. We anticipate that our general and administrative expenses will continue to increase in future periods, reflecting continued and increasing costs associated with: ● support for our research and development activities; ● stock compensation granted to key employees and non-employees; ● support of business dev

filing / Aug 14, 2026 / receipt

decrease in travel expense. We anticipate that our general and administrative expenses will continue to increase in future periods, reflecting continued and increasing costs associated with: ● support for our research and development activities; ● stock compensation granted to key employees and non-employees; ● support of business development activities; and ● increased professional fees and other costs ass

filing / Aug 14, 2026 / receipt

Office lease ROU asset $ - $ 31,075 Less accumulated amortization - ( 26,423 ) Total ROU asset, net $ - $ 4,652 Operating lease liability for operating leases was recorded in the accompanying unaudited condensed consolidated balance sheets as follows: June 30, 2026 December 31, 2025 Current portion of operating lease liability $ - $ 5,678 Long-term portion of operating lease liability - - Total operatin

filing / Aug 14, 2026 / receipt

Office Lease On December 9, 2024, the Company and the landlord entered into a lease agreement (the “December 2024 Lease”).

filing / Aug 14, 2026 / receipt

Office lease right-of-use asset $ - $ 31,075 Less accumulated amortization - ( 26,423 ) Total right-of-use asset, net $ - $ 4,652 20 HOTH THERAPEUTICS, INC.

filing / May 15, 2026 / receipt

Office Lease Effective November 2023, the Company leased office space for a two-year term. The Company’s office lease contained a renewal option.

filing / May 15, 2026 / receipt

Submission to European Medical Agency for Clinical Trial Expansion in EU

ir_statement / Sep 8, 2026 / receipt